Form 8-K - Current report

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934


Date of Report (Date of Earliest Event Reported)			November 2, 2023

TELEFLEX INCORPORATED

(Exact name of Registrant as Specified in Its Charter)


Delaware	1-5353	23-1147939
(State or Other Jurisdiction of Incorporation or Organization)	(Commission File Number)	(IRS Employer Identification No.)

550 E. Swedesford Rd., Suite 400

Wayne,

19087

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code

(610)

225-6800


Not applicable
(Former Name or Former Address, If Changed Since Last Report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $1 per share

TFX

New York Stock Exchange

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On November 2, 2023, Teleflex Incorporated (the “Company”) issued a press release (the “Press Release”) announcing its financial results for the quarter ended October 1, 2023. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report.

In addition to the financial information included in the Press Release that has been prepared in accordance with generally accepted accounting principles in the United States (“GAAP”), the Press Release includes certain non-GAAP financial measures. These measures include constant currency revenue growth and adjusted diluted earnings per share. Constant currency revenue growth is based upon net revenues, adjusted to eliminate the impact of translating the results of international subsidiaries at different currency exchange rates from period to period. The impact of changes in foreign currency may vary significantly from period to period, and generally are outside of the control of our management. We believe that this measure facilitates a comparison of our operating performance exclusive of fluctuations that do not reflect our underlying performance or business trends. Adjusted diluted earnings per share is based upon diluted earnings per share available to common stockholders, the most directly comparable GAAP measure, adjusted to exclude, depending on the period presented, the impact (net of tax) of (i) restructuring, restructuring related and impairment items; (ii) acquisition, integration and divestiture related items; (iii) other items identified in the reconciliation tables set forth in the Press Release, as applicable; (iv) costs incurred in connection with our implementation of a new global enterprise resource planning system and related information technology transition costs; (v) pension termination and related charges; (vi) certain expenditures associated with the registration of medical devices under the European Union Medical Device Regulation; (vii) intangible amortization expense; and (viii) tax adjustments. Management does not believe that any of the excluded items are indicative of our underlying core performance or business trends.

Management uses these non-GAAP financial measures to assess the Company's financial performance, make operating decisions, allocate financial resources, provide guidance on possible future results, and assist in its evaluation of period-to-period and peer comparisons. The non-GAAP measures may be useful to investors because they provide insight into management’s assessment of our business, and provide supplemental information pertinent to a comparison of period-to-period results of our ongoing operations. The non-GAAP financial measures are presented in addition to results presented in accordance with GAAP and should not be relied upon as a substitute for GAAP financial measures. Moreover, our non-GAAP financial measures may not be comparable to similarly titled measures used by other companies.

The information furnished pursuant to Item 2.02 of this Current Report, including Exhibit 99.1 hereto, shall not be considered “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of such section, nor shall it be incorporated by reference into future filings by the Company under the Securities Act of 1933, as amended, or under the Securities Exchange Act of 1934, as amended, unless the Company expressly sets forth in such future filing that such information is to be considered "filed" or incorporated by reference therein.

Item 7.01. Regulation FD Disclosure.

In connection with the conference call to be held by the Company on November 2, 2023 to discuss its financial results for the quarter ended October 1, 2023, the Company plans to reference a slide presentation, which will be made available in advance of the call through the Company’s website. A copy of the slide presentation is furnished as Exhibit 99.2 to this Current Report.

The information furnished pursuant to Item 7.01 of this Current Report, including Exhibit 99.2, shall not be considered “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of such section, nor shall it be incorporated by reference into future filings by the Company under the Securities Act of 1933, as amended or under the Securities Exchange Act of 1934, as amended, unless the Company expressly sets forth in such future filing that such information is to be considered “filed” or incorporated by reference therein.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

99.1 Earnings Press Release, dated November 2 , 2023

99.2 Earnings Conference Call Slide Presentation

104 The Cover Page from this Current Report on Form 8-K, formatted in Inline XBRL

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: November 2, 2023			TELEFLEX INCORPORATED By: /s/ Thomas E. Powell Name: Thomas E. Powell Title: Executive Vice President and Chief Financial Officer

Exhibit 99.1


FOR IMMEDIATE RELEASE			November 2, 2023

Teleflex Reports Third Quarter Financial Results and Full Year 2023 Outlook

Wayne, PA -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the third quarter ended October 1, 2023.

Third quarter financial summary

•Revenues of $746.4 million, up 8.7% compared to the prior year period; up 7.4% on a constant currency basis

•GAAP diluted EPS from continuing operations of $2.91, compared to $2.16 in the prior year period

•Adjusted diluted EPS from continuing operations of $3.64, compared to $3.27 in the prior year period

2023 guidance summary

•Narrowing GAAP revenue growth guidance to 6.25% to 6.45%

•Raising constant currency revenue growth guidance range to 6.4% to 6.6%

•Raising GAAP EPS from continuing operations guidance to $7.95 to $8.15

•Narrowing adjusted diluted EPS from continuing operations guidance to $13.30 to $13.50

"Following a strong first half performance, our third quarter built upon Teleflex’s durable growth profile with a 7.4% constant currency revenue increase year-over-year. We witnessed stability in surgical procedures, continued strength in our Asia Pacific market, and healthy increases in our Interventional and OEM businesses" said Liam Kelly, Teleflex's Chairman, President and Chief Executive Officer. "We also recently completed our acquisition of Palette Life Sciences AB, which will enable our Interventional Urology business unit to bring urologists, radiation oncologists, and other specialists more innovative technologies that can positively impact patient care. Our updated constant currency growth guidance reflects the stronger than expected performance over the nine-months of 2023. In addition, the guidance includes the expected contribution from our acquisition of Palette partly offset by a loss of revenue from the termination of the manufacturing transition services agreement associated with the divestiture of certain respiratory assets to Medline, which is now expected to occur earlier than originally planned.”

NET REVENUE BY SEGMENT

The following table provides information regarding net revenues in each of the Company's reportable operating segments for the three and nine months ended October 1, 2023 and September 25, 2022 on both a GAAP and constant currency basis.


	Three Months Ended		% Increase / (Decrease)
	October 1, 2023	September 25, 2022	Reported Revenue Growth	Currency Impact	Constant Currency Revenue Growth
Americas	$428.2	$405.1	5.7%	0.2%	5.5%
EMEA	142.7	128.4	11.1%	7.1%	4.0%
Asia	93.2	82.0	13.6%	(3.5)%	17.1%
OEM	82.3	71.3	15.5%	1.5%	14.0%
Consolidated	$746.4	$686.8	8.7%	1.3%	7.4%


	Nine Months Ended		% Increase / (Decrease)
	October 1, 2023	September 25, 2022	Reported Revenue Growth	Currency Impact	Constant Currency Revenue Growth
Americas	$1,264.7	$1,195.7	5.8%	—%	5.8%
EMEA	433.9	410.5	5.7%	0.8%	4.9%
Asia	258.6	227.8	13.5%	(5.9)%	19.4%
OEM	243.4	199.0	22.4%	0.5%	21.9%
Consolidated	$2,200.6	$2,033.0	8.2%	(0.5)%	8.7%

NET REVENUE BY GLOBAL PRODUCT CATEGORY

The following table provides information regarding net revenues in each of the Company's global product categories for the three and nine months ended October 1, 2023 and September 25, 2022 on both a GAAP and constant currency basis.


	Three Months Ended		% Increase / (Decrease)
	October 1, 2023	September 25, 2022	Reported Revenue Growth	Currency Impact	Constant Currency Revenue Growth
Vascular Access	$169.9	$167.1	1.7%	1.4%	0.3%
Interventional	134.1	108.7	23.3%	0.9%	22.4%
Anesthesia	97.6	97.6	—%	1.3%	(1.3)%
Surgical	112.8	93.1	21.1%	0.5%	20.6%
Interventional Urology	73.6	79.0	(6.8)%	—%	(6.8)%
OEM	82.3	71.3	15.5%	1.5%	14.0%
Other	76.1	69.9	8.8%	3.5%	5.3%
Consolidated	$746.4	$686.8	8.7%	1.3%	7.4%


	Nine Months Ended		% Increase / (Decrease)
	October 1, 2023	September 25, 2022	Reported Revenue Growth	Currency Impact	Constant Currency Revenue Growth
Vascular Access	$521.3	$497.2	4.9%	(0.4)%	5.3%
Interventional	375.8	319.9	17.5%	(0.6)%	18.1%
Anesthesia	291.8	289.2	0.9%	(0.3)%	1.2%
Surgical	317.8	282.5	12.5%	(1.6)%	14.1%
Interventional Urology	226.8	233.7	(2.9)%	(0.1)%	(2.8)%
OEM	243.4	199.0	22.4%	0.5%	21.9%
Other	223.7	211.5	5.7%	0.2%	5.5%
Consolidated	$2,200.6	$2,033.0	8.2%	(0.5)%	8.7%

OTHER FINANCIAL HIGHLIGHTS

•Depreciation expense, amortization of intangible assets and deferred financing charges for the nine months ended October 1, 2023 totaled $180.5 million compared to $174.1 million for the prior year period.

•Cash and cash equivalents at October 1, 2023 were $881.5 million compared to $292.0 million at December 31, 2022.

•Net accounts receivable at October 1, 2023 were $425.2 million compared to $408.8 million at December 31, 2022.

•Inventories at October 1, 2023 were $625.1 million compared to $578.5 million at December 31, 2022.

2023 OUTLOOK

The Company narrowed its full year 2023 GAAP revenue growth outlook to 6.25% to 6.45%, reflecting our estimate of an approximately 0.15% negative impact of foreign exchange rate fluctuations. On a constant currency basis, the Company increased its full year 2023 revenue growth outlook of 6.40% to 6.60% year-over-year.

The Company raised its full year 2023 GAAP diluted earnings per share from continuing operations guidance to $7.95 to $8.15. The Company narrowed its 2023 adjusted diluted earnings per share from continuing operations guidance to $13.30 to $13.50, representing growth of 1.8% to 3.4% year-over-year.

Forecasted 2023 Constant Currency Revenue Growth Reconciliation


	Low	High
Forecasted 2023 GAAP revenue growth	6.25%	6.45%
Estimated impact of foreign currency exchange rate fluctuations	(0.15)%	(0.15)%
Forecasted 2023 constant currency revenue growth	6.40%	6.60%

Forecasted 2023 Adjusted Diluted Earnings Per Share From Continuing Operations Reconciliation


	Low	High
Forecasted GAAP diluted earnings per share from continuing operations	$7.95	$8.15
Restructuring, restructuring related and impairment items, net of tax	$0.61	$0.61
Acquisition, integration and divestiture related items, net of tax	$(0.29)	$(0.29)
Other items, net of tax	$0.11	$0.11
Pension termination and related charges, net of tax	$0.80	$0.80
ERP Implementation, net of tax	$0.05	$0.05
MDR, net of tax	$0.60	$0.60
Intangible amortization expense, net of tax	$3.47	$3.47
Forecasted adjusted diluted earnings per share from continuing operations, net of tax	$13.30	$13.50

CONFERENCE CALL WEBCAST AND ADDITIONAL INFORMATION

A webcast of Teleflex's third quarter 2023 investor conference call can be accessed live from a link on the Company's website at teleflex.com. The call will begin at 8:00 am ET on November 2, 2023.

An audio replay of the investor call will be available beginning at 11:00 am ET on November 2, 2023, either on the Teleflex website or by telephone. The call can be accessed by dialing 1 800 770 2030 (U.S.) or 1 647 362 9199 (all other locations). The confirmation code is 87648.

ADDITIONAL NOTES

References in this release to the impact of foreign currency exchange rate fluctuations on adjusted diluted earnings per share include both the impact of translating foreign currencies into U.S. dollars and the impact of foreign currency exchange rate fluctuations on foreign currency denominated transactions.

In the discussion of segment results, "new products" refers to products for which we initiated commercial sales within the past 36 months and "existing products" refers to products we have sold commercially for more than 36 months.

Certain financial information is presented on a rounded basis, which may cause minor differences. Segment results and commentary exclude the impact of discontinued operations.

NOTES ON NON-GAAP FINANCIAL MEASURES

We report our financial results in accordance with accounting principles generally accepted in the United States, commonly referred to as “GAAP.” In this press release, we provide supplemental information, consisting of the following non-GAAP financial measures: constant currency revenue growth and adjusted diluted earnings per share. These non-GAAP measures are described in more detail below. Management uses these financial measures to assess Teleflex’s financial performance, make operating decisions, allocate financial resources, provide guidance on possible future results, and assist in its evaluation of period-to-period and peer comparisons. The non-GAAP measures may be useful to investors because they provide insight into management’s assessment of our business, and provide supplemental information pertinent to a comparison of period-to-period results of our ongoing operations. The non-GAAP financial measures are presented in addition to results presented in accordance with GAAP and should not be relied upon as a substitute for GAAP financial measures. Moreover, our non-GAAP financial measures may not be comparable to similarly titled measures used by other companies.

Tables reconciling changes in historical constant currency net revenues to historical GAAP net revenues are set forth above under “Net Revenue by Segment" and "Net Revenue by Global Product Category". Tables reconciling historical adjusted diluted earnings per share from continuing operations to historical GAAP diluted earnings per share from continuing operations are set forth below.

Constant currency revenue growth: This non-GAAP measure is based upon net revenues, adjusted to eliminate the impact of translating the results of international subsidiaries at different currency exchange rates from period to period. The impact of changes in foreign currency may vary significantly from period to period, and such changes generally are outside of

the control of our management. We believe that this measure facilitates a comparison of our operating performance exclusive of currency exchange rate fluctuations that do not reflect our underlying performance or business trends.

Adjusted diluted earnings per share: This non-GAAP measure is based upon diluted earnings per share from continuing operations, the most directly comparable GAAP measure, adjusted to exclude, depending on the period presented, the items described below. Management does not believe that any of the excluded items are indicative of our underlying core performance or business trends.

Restructuring, restructuring related and impairment items - Restructuring programs involve discrete initiatives designed to, among other things, consolidate or relocate manufacturing, administrative and other facilities, outsource distribution operations, improve operating efficiencies and integrate acquired businesses. Depending on the specific restructuring program involved, our restructuring charges may include employee termination, contract termination, facility closure, employee relocation, equipment relocation, outplacement and other exit costs associated with the restructuring program. Restructuring related charges are directly related to our restructuring programs and consist of facility consolidation costs, including accelerated depreciation expense related to facility closures, costs to transfer manufacturing operations between locations, and retention bonuses offered to certain employees as an incentive for them to remain with our company after completion of the restructuring program. Impairment charges occur if, due to events or changes in circumstances, we determine that the carrying value of an asset exceeds its fair value. Impairment charges do not directly affect our liquidity, but could have a material adverse effect on our reported financial results.

Acquisition, integration and divestiture related items - Acquisition and integration expenses are incremental charges, other than restructuring or restructuring related expenses, that are directly related to specific business or asset acquisition transactions. These charges may include, among other things, professional, consulting and other fees; systems integration costs; legal entity restructuring expense; inventory step-up amortization (amortization, through cost of goods sold, of the increase in fair value of inventory resulting from a fair value calculation as of the acquisition date); fair value adjustments to contingent consideration liabilities; and bridge loan facility and backstop financing fees in connection with loan facilities that ultimately were not utilized. Divestiture related activities involve specific business or asset sales. Depending primarily on the terms of a divestiture transaction, the carrying value of the divested business or assets on our financial statements and other costs we incur as a direct result of the divestiture transaction, we may recognize a gain or loss in connection with the divestiture related activities.

Other - These are discrete items that occur sporadically and can affect period-to-period comparisons.

Pension termination and related charges - These adjustments represent charges associated with the planned termination of the Teleflex Incorporated Retirement Income Plan, a frozen U.S. defined benefit pension plan, and related direct incremental costs. These charges and costs do not represent normal and recurring operating expenses, will be inconsistent in amounts and frequency, and are not expected to recur once the plan termination process has been completed. Accordingly, management has excluded these amounts to facilitate an evaluation of our current operating performance and a comparison to our past operating performance.

European medical device regulation - The European Union (“EU”) has adopted the EU Medical Device Regulation (“MDR”), which replaces the existing Medical Devices Directive (“MDD”) and imposes more stringent requirements for the marketing and sale of medical devices in the EU, including requirements affecting clinical evaluations, quality systems and post-market surveillance. The MDR requirements became effective in May 2021, although certain devices that previously satisfied MDD requirements can continue to be marketed in the EU until May 2024, subject to certain limitations. Significantly, the MDR will require the re-registration of previously approved medical devices. As a result, Teleflex will incur expenditures in connection with the new registration of medical devices that previously had been registered under the MDD. Therefore, these expenditures are not considered to be ordinary course expenditures in connection with regulatory matters (in contrast, no adjustment has been made to exclude expenditures related to the registration of medical devices that were not registered previously under the MDD).

Intangible amortization expense - Certain intangible assets, including customer relationships, intellectual property, distribution rights, trade names and non-competition agreements, initially are recorded at historical cost and then amortized over their respective estimated useful lives. The amount of such amortization can vary from period to period as a result of, among other things, business or asset acquisitions or dispositions.

ERP implementation - These adjustments represent direct and incremental costs incurred in connection with our implementation of a new global enterprise resource planning ("ERP") solution and related IT transition costs. An implementation of this scale is a significant undertaking and will require substantial time and attention of management and key employees. The associated costs do not represent normal and recurring operating expenses and will be inconsistent in amounts and frequency making it difficult to contribute to a meaningful evaluation of our operating performance.

Tax adjustments - These adjustments represent the impact of the expiration of applicable statutes of limitations for prior year returns, the resolution of audits, the filing of amended returns with respect to prior tax years and/or tax law or certain other discrete changes affecting our deferred tax liability.

Reconciliation of Consolidated Statement of Income Items (Dollars in millions, except per share data)


Three Months Ended October 1, 2023
	Gross margin	Selling, general and administrative expenses (1)	Research and development expenses (1)	Operating margin (2)	Income before income taxes	Income tax expense	Effective income tax rate	Diluted earnings per share from continuing operations
GAAP Basis	55.8%	28.6%	5.0%	22.1%	$149.6	$11.9	8.0%	$2.91
Adjustments
Restructuring, restructuring related and impairment items (A)	0.5	—	—	0.6	4.7	0.7		0.08
Acquisition, integration and divestiture related items (B)	—	2.0	—	(2.0)	(14.8)	0.2		(0.32)

ERP implementation	—	—	—	—	0.3	0.1		0.00
MDR	—	—	(0.8)	0.8	5.7	—		0.12
Intangible amortization expense	3.1	(2.6)	—	5.7	41.6	2.1		0.85
Tax adjustments	—	—	—	—	—	—		—
Adjustments total	3.6	(0.6)	(0.8)	5.1	37.5	3.1		0.73
Adjusted basis	59.4%	28.0%	4.2%	27.2%	$187.1	$15.0	8.0%	$3.64


Three Months Ended September 25, 2022
	Gross margin	Selling, general and administrative expenses (1)	Research and development expenses (1)	Operating margin (2)	Income before income taxes	Income tax expense	Effective income tax rate	Diluted earnings per share from continuing operations
GAAP Basis	54.4%	30.5%	5.5%	19.3%	$119.2	$17.3	14.5%	$2.16
Adjustments
Restructuring, restructuring related and impairment items (A)	1.0	—	—	1.1	7.5	0.5		0.15
Acquisition, integration and divestiture related items (B)	—	(0.2)	—	(0.8)	(5.2)	(1.4)		(0.08)

ERP Implementation	—	—	—	—	—	—		—
MDR	—	—	(1.3)	1.3	8.8	—		0.19
Intangible amortization expense	3.3	(2.6)	—	6.0	40.9	1.5		0.83
Tax adjustments	—	—	—	—	—	(1.1)		0.02
Adjustments total	4.3	(2.8)	(1.3)	7.6	52.0	(0.5)		1.11
Adjusted basis	58.7%	27.7%	4.2%	26.9%	$171.2	$16.8	9.8%	$3.27

Notes: (1) Selling, general and administrative expenses and research and development expenses are shown as a percentage of net revenues.

(2) Operating margin defined as Income from continuing operations before interest, loss on extinguishment of debt and taxes as a percentage of net revenues.

Totals may not sum due to rounding.


Nine Months Ended October 1, 2023
	Gross margin	Selling, general and administrative expenses (1)	Research and development expenses (1)	Operating margin (2)	Income before income taxes	Income tax expense	Effective income tax rate	Diluted earnings per share from continuing operations
GAAP Basis	55.2%	30.4%	5.4%	19.3%	$374.0	$47.7	12.7%	$6.90
Adjustments
Restructuring, restructuring related and impairment items (A)	0.9	—	(0.1)	1.3	27.5	4.2		0.49
Acquisition, integration and divestiture related items (B)	—	0.9	—	(0.9)	(19.3)	0.3		(0.41)

ERP Implementation	—	(0.1)	—	0.1	2.8	0.7		0.05
MDR	—	—	(1.1)	1.1	23.6	—		0.50
Intangible amortization expense	3.2	(2.6)	—	5.6	125.3	6.2		2.51
Tax adjustments	—	—	—	—	—	(4.8)		0.10
Adjustments total	4.1	(1.8)	(1.2)	7.2	159.9	6.6		3.24
Adjusted basis	59.3%	28.6%	4.2%	26.5%	$533.9	$54.3	10.2%	$10.14


Nine Months Ended September 25, 2022
	Gross margin	Selling, general and administrative expenses (1)	Research and development expenses (1)	Operating margin (2)	Income before income taxes	Income tax expense	Effective income tax rate	Diluted earnings per share from continuing operations
GAAP Basis	54.5%	31.0%	5.5%	18.3%	$336.5	$51.7	15.4%	$6.02
Adjustments
Restructuring, restructuring related and impairment items (A)	1.1	—	—	1.2	25.3	2.3		0.49
Acquisition, integration and divestiture related items (B)	—	(0.1)	—	(0.2)	(4.5)	(1.4)		(0.07)

ERP Implementation	—	—	—	—	—	—		—
MDR	—	—	(1.5)	1.4	29.4	—		0.62
Intangible amortization expense	3.3	(2.7)	—	6.0	122.0	4.6		2.48
Tax adjustments	—	—	—	—	—	—		—
Adjustments total	4.4	(2.8)	(1.5)	8.4	172.2	5.5		3.52
Adjusted basis	58.9%	28.2%	4.0%	26.7%	$508.7	$57.2	11.2%	$9.54

Notes: (1) Selling, general and administrative expenses and research and development expenses are shown as a percentage of net revenues.

(2) Operating margin defined as Income from continuing operations before interest, loss on extinguishment of debt and taxes as a percentage of net revenues.

Totals may not sum due to rounding.

Tickmarks to Reconciliation Tables

(A)Restructuring, restructuring related and impairment items – For the three months ended October 1, 2023, pre-tax restructuring charges were $0.2 million and restructuring related charges were $4.5 million. For the three months ended September 25, 2022, pre-tax restructuring charges were $0.6 million and restructuring related charges were $6.9 million. For the nine months ended October 1, 2023, pre-tax restructuring charges were $4.0 million and restructuring related charges were $23.6 million. For the nine months ended September 25, 2022, pre-tax restructuring charges were $1.5 million; restructuring related charges were $22.4 million, and impairment charges were $1.5 million.

(B)Acquisition, integration and divestiture related items – For the three months ended October 1, 2023, these credits and charges primarily related to a credit recognized due to a decrease in contingent consideration expense resulting from changes in the estimated fair value of our contingent consideration and charges associated with the acquisition of Palette Life Sciences AB. For the three months ended September 25, 2022, these charges related to the acquisition of Standard Bariatrics, Inc. and the gain related to a sale of a building. For the nine months ended October 1, 2023, these credits and charges primarily related to a credit recognized due to a decrease in contingent consideration expense resulting from changes in the estimated fair value of our contingent consideration and charges associated with the acquisition of Palette Life Sciences AB. For the nine months ended September 25, 2022, these charges related to the acquisition of Standard Bariatrics, Inc., the divestiture of respiratory assets, and the gain related to a sale of a building.

ABOUT TELEFLEX INCORPORATED

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation - a relentless pursuit of identifying unmet clinical needs - to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular access, interventional cardiology and radiology, anesthesia, emergency medicine, surgical, urology and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, LMA®, Pilling®, QuikClot®, Rusch®, UroLift® and Weck® - trusted brands united

by a common sense of purpose.

CAUTION CONCERNING FORWARD-LOOKING INFORMATION

This press release contains forward-looking statements, including, but not limited to, our expectation that our acquisition of Palette Life Sciences AB will enable our Interventional Urology business unit to bring urologists, radiation oncologists, and other specialists more innovative technologies that can positively impact patient care; forecasted 2023 GAAP and constant currency revenue growth and GAAP and adjusted diluted earnings per share; our estimates regarding the projected impact of foreign currency exchange rate fluctuations on our 2023 financial results; and our estimates regarding the projected impact of the Palette acquisition and the termination of the manufacturing transition services agreement associated with the divestiture of certain respiratory assets to Medline on our 2023 financial results. Actual results could differ materially from those in the forward-looking statements due to, among other things, delays or cancellations in shipments; demand for and market acceptance of new and existing products; our inability to provide products to our customers, which may be due to, among other things, events that impact key distributors, suppliers and third-party vendors that sterilize our products; our inability to integrate acquired businesses into our operations, realize planned synergies and operate such businesses profitably in accordance with our expectations; the inability of acquired businesses to generate revenues in accordance with our expectations; our inability to effectively execute our restructuring plans and programs; our inability to realize anticipated savings from restructuring plans and programs; the impact of healthcare reform legislation and proposals to amend, replace or repeal the legislation; changes in Medicare, Medicaid and third party coverage and reimbursements; the impact of enacted tax legislation and related regulations; competitive market conditions and resulting effects on revenues and pricing; increases in raw material costs that cannot be recovered in product pricing; global economic factors, including currency exchange rates, interest rates, trade disputes, sovereign debt issues and international conflicts and hostilities, such as the ongoing conflicts in the Ukraine and Israel; public health epidemics, including COVID-19; difficulties in entering new markets; general economic conditions; and other factors described or incorporated in our filings with the Securities and Exchange Commission, including our most recently filed Annual Report on Form 10-K. We expressly disclaim any obligation to update forward-looking statements, except as otherwise specifically stated by us or as required by law or regulation.

TELEFLEX INCORPORATED

CONSOLIDATED STATEMENTS OF INCOME

(Unaudited)


	Three Months Ended				Nine Months Ended
	October 1, 2023		September 25, 2022		October 1, 2023		September 25, 2022
	(Dollars and shares in thousands, except per share)
Net revenues	$	746,389	$	686,788	$	2,200,580	$	2,033,045
Cost of goods sold	330,078		312,833		985,066		924,024
Gross profit	416,311		373,955		1,215,514		1,109,021
Selling, general and administrative expenses	213,194		209,616		669,216		630,373
Research and development expenses	37,576		37,770		118,493		111,064
Restructuring and impairment charges	231		628		3,960		2,950
Gains on sale of asset and business	—		(6,504)		—		(6,504)
Income from continuing operations before interest and taxes	165,310		132,445		423,845		371,138
Interest expense	23,192		13,375		59,291		35,212
Interest income	(7,487)		(126)		(9,486)		(577)

Income from continuing operations before taxes	149,605		119,196		374,040		336,503
Taxes on income from continuing operations	11,935		17,315		47,651		51,700
Income from continuing operations	137,670		101,881		326,389		284,803
Operating (loss) income from discontinued operations	(687)		19		(1,512)		(329)
Tax (benefit) expense on operating loss from discontinued operations	(157)		5		(346)		(76)
(Loss) income from discontinued operations	(530)		14		(1,166)		(253)
Net income	$	137,140	$	101,895	$	325,223	$	284,550
Earnings per share:
Basic:
Income from continuing operations	$	2.93	$	2.17	$	6.95	$	6.07
Loss from discontinued operations	(0.01)		—		(0.03)		—
Net income	$	2.92	$	2.17	$	6.92	$	6.07
Diluted:
Income from continuing operations	$	2.91	$	2.16	$	6.90	$	6.02
Loss from discontinued operations	(0.01)		—		(0.02)		(0.01)
Net income	$	2.90	$	2.16	$	6.88	$	6.01
Weighted average common shares outstanding
Basic	46,992		46,906		46,974		46,894
Diluted	47,299		47,263		47,304		47,337

TELEFLEX INCORPORATED

CONSOLIDATED BALANCE SHEETS

(Unaudited)


	October 1, 2023		December 31, 2022
	(Dollars in thousands)
ASSETS
Current assets
Cash and cash equivalents	$	881,499	$	292,034
Accounts receivable, net	425,194		408,834
Inventories	625,075		578,507
Prepaid expenses and other current assets	138,657		125,084
Prepaid taxes	26,846		6,524

Total current assets	2,097,271		1,410,983
Property, plant and equipment, net	464,467		447,205
Operating lease assets	123,604		131,211
Goodwill	2,528,305		2,536,730
Intangible assets, net	2,180,539		2,306,165
Deferred tax assets	6,167		6,402
Other assets	93,281		89,367

Total assets	$	7,493,634	$	6,928,063
LIABILITIES AND EQUITY
Current liabilities
Current borrowings	$	87,500	$	87,500
Accounts payable	130,686		126,807
Accrued expenses	133,067		140,644

Payroll and benefit-related liabilities	127,101		133,092
Accrued interest	17,428		5,332
Income taxes payable	24,375		24,736
Other current liabilities	65,265		63,381

Total current liabilities	585,422		581,492
Long-term borrowings	1,950,123		1,624,023
Deferred tax liabilities	389,080		388,886
Pension and postretirement benefit liabilities	30,051		31,394
Noncurrent liability for uncertain tax positions	6,545		5,805

Noncurrent operating lease liabilities	111,810		120,437
Other liabilities	106,555		154,058
Total liabilities	3,179,586		2,906,095
Commitments and contingencies
Total shareholders' equity	4,314,048		4,021,968
Total liabilities and shareholders' equity	$	7,493,634	$	6,928,063

TELEFLEX INCORPORATED

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)


	Nine Months Ended
	October 1, 2023		September 25, 2022
	(Dollars in thousands)
Cash flows from operating activities of continuing operations:
Net income	$	325,223	$	284,550
Adjustments to reconcile net income to net cash provided by operating activities:
Loss from discontinued operations	1,166		253
Depreciation expense	52,687		49,076
Intangible asset amortization expense	125,230		121,904
Deferred financing costs and debt discount amortization expense	2,547		3,150



Changes in contingent consideration	(24,482)		237
Assets impairment charges	—		1,497
Stock-based compensation	22,135		19,804
Gain on sale of business	—		(6,504)
Deferred income taxes, net	2,076		63
Payments for contingent consideration	(289)		(2,983)
Interest benefit on swaps designated as net investment hedges	(15,459)		(15,677)
Other	4,743		(3,953)
Changes in assets and liabilities, net of effects of acquisitions and disposals:
Accounts receivable	(18,313)		(36,402)
Inventories	(50,702)		(85,293)
Prepaid expenses and other assets	7,487		21,298
Accounts payable, accrued expenses and other liabilities	(16,674)		(26,726)
Income taxes receivable and payable, net	(45,014)		(79,879)
Net cash provided by operating activities from continuing operations	372,361		244,415
Cash flows from investing activities of continuing operations:
Expenditures for property, plant and equipment	(63,768)		(52,648)
Proceeds from sale of business and assets	—		12,434
Payments for businesses and intangibles acquired, net of cash acquired	(205)		(27,308)

Net interest proceeds on swaps designated as net investment hedges	10,275		10,314
Proceeds from sales of investments	7,300		7,300
Purchase of investments	(11,300)		(7,300)
Net cash used in investing activities from continuing operations	(57,698)		(57,208)
Cash flows from financing activities of continuing operations:
Proceeds from new borrowings	646,000		—
Reduction in borrowings	(321,625)		(144,250)

Net proceeds (payments) from share based compensation plans and related tax impacts	534		(4,398)
Payments for contingent consideration	(949)		(3,885)
Dividends paid	(47,919)		(47,840)

Net cash provided by (used in) financing activities from continuing operations	276,041		(200,373)
Cash flows from discontinued operations:
Net cash used in operating activities	(579)		(482)
Net cash used in discontinued operations	(579)		(482)
Effect of exchange rate changes on cash and cash equivalents	(660)		(34,177)
Net increase (decrease) in cash and cash equivalents	589,465		(47,825)
Cash and cash equivalents at the beginning of the period	292,034		445,084
Cash and cash equivalents at the end of the period	$	881,499	$	397,259

Contacts:

Teleflex Incorporated:

Lawrence Keusch

Vice President, Investor Relations and Strategy Development

investors.teleflex.com

610-948-2836

Third Quarter 2023 Earnings Conference Call Teleflex Incorporated Exhibit 99.2

2 The release, accompanying slides, and replay webcast are available online at www.teleflex.com (click on Investors) An audio replay of the call will be available beginning at 11:00 am Eastern Time on November 2, 2023 either on the Teleflex website or by telephone. The call can be accessed by dialing 1 800 770 2030 (U.S.) or 1 647 362 9199 (all other locations). The confirmation code is 87648. Conference Call Logistics

3 Today’s Speakers Liam Kelly Chairman, President and CEO Lawrence Keusch VP, Investor Relations and Strategy Development Thomas Powell Executive VP and CFO

4 This presentation contains forward-looking statements, including, but not limited to our expectations that we will be able to leverage our urologist call point with respect to the Palette business and that the Palette business will provide us with access to radiation oncologists; estimates with respect to the number of new cases of prostate cancer that will be diagnosed in the United States in 2023; our estimates with respect to the financial performance of Palette, including forecasted 2023 sales and expected 2024 sales growth; expected impacts of the Palette acquisition on our financial results, including with respect to our adjusted gross and operating margins and adjusted earnings per share; our forecasted 2023 GAAP and constant currency revenue growth, GAAP and adjusted gross and operating margins and GAAP and adjusted earnings per share and, in each case, our estimates with respect to the items expected to impact those forecasted results; our expectation that our performance for the third quarter of 2023 and the stable to improving macro environment keep us well-positioned to deliver on our 2023 financial guidance; our expectation that Palette will meaningfully contribute to our growth and enhance our adjusted margins in the coming years; and other matters which inherently involve risks and uncertainties which could cause actual results to differ from those projected or implied in the forward–looking statements. These risks and uncertainties are addressed in our SEC filings, including our most recent Form 10-K. We expressly disclaim any obligation to update forward-looking statements, except as otherwise specifically stated by us or as required by law or regulation. Note on Forward-Looking Statements Note on Non-GAAP Financial Measures Additional Notes This document contains certain highlights with respect to our third quarter 2023 and developments and does not purport to be a complete summary thereof. Accordingly, we encourage you to read our Earnings Release for the quarter ended October 1, 2023 located in the investor section of our website at www.teleflex.com and our Quarterly Report on Form 10-Q for the quarter ended October 1, 2023 to be filed with the Securities and Exchange Commission. Unless otherwise noted, the following slides reflect continuing operations. This presentation refers to certain non-GAAP financial measures, including, but not limited to, constant currency revenue growth, adjusted diluted earnings per share, adjusted gross and operating margins and adjusted tax rate. These non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Tables reconciling these non-GAAP financial measures to the most comparable GAAP financial measures are contained within this presentation and the appendices at the end of this presentation.

5 Liam Kelly - Chairman, President and CEO Executive Overview

6 Q3'23 Highlights ◦ Q3'23 constant currency revenue grew 7.4% year-over-year ◦ Q3'23 adjusted gross margin of 59.4% and adjusted operating margin of 27.2% ◦ Q3'23 adjusted EPS of $3.64, an 11.3% increase year-over-year Q3 Performance Summary 2023 Financial Guidance Note: See tables appearing in this presentation and the appendices hereto for reconciliations of non-GAAP financial information. ◦ Increased 2023 constant currency revenue growth guidance to 6.40% to 6.60% ◦ Narrowed 2023 adjusted earnings per share guidance to $13.30 to $13.50

7 Q3'23 Segment Revenue Review Three Months Ended % Increase/ Decrease Dollars in Millions October 1, 2023 September 25, 2022 Reported Revenue Growth Currency Impact Constant Currency Growth Americas $428.2 $405.1 5.7% 0.2% 5.5% EMEA $142.7 $128.4 11.1% 7.1% 4.0% Asia $93.2 $82.0 13.6% (3.5)% 17.1% OEM $82.3 $71.3 15.5% 1.5% 14.0% Consolidated $746.4 $686.8 8.7% 1.3% 7.4%

8 Q3'23 Global Product Category Revenue Review Three Months Ended % Increase/ Decrease Dollars in Millions October 1, 2023 September 25, 2022 Reported Revenue Growth Currency Impact Constant Currency Growth Vascular Access $169.9 $167.1 1.7% 1.4% 0.3% Interventional $134.1 $108.7 23.3% 0.9% 22.4% Anesthesia $97.6 $97.6 —% 1.3% (1.3)% Surgical $112.8 $93.1 21.1% 0.5% 20.6% Interventional Urology $73.6 $79.0 (6.8)% —% (6.8)% OEM $82.3 $71.3 15.5% 1.5% 14.0% Other(1) $76.1 $69.9 8.8% 3.5% 5.3% Consolidated $746.4 $686.8 8.7% 1.3% 7.4% ◦ 1. Includes revenues generated from sales of the Company’s respiratory and urology products (other than interventional urology products). (1) Includes revenues generated from the Company’s respiratory and urology products (other than interventional urology products), and products sold to Medline pursuant to the manufacturing and supply transition agreement executed in June of 2021.

9 Acquisition of Palette Life Sciences AB • $600 million cash upfront payment • $50 million in contingent consideration payments upon the achievement of certain commercial milestones • Acquisition closed October 10, 2023 CAUTION: Federal (USA) law restricts these devices to sale or use by or on the order of a physician. Refer to the Instructions for Use for a complete listing of the indications, contraindications, warnings, and precautions. Information in this document is not a substitute for the product Instructions for Use. Not all products may be available in all countries. TRANSACTION DETAILS

10 Acquisition of Palette Life Sciences AB Expands interventional urology portfolio into adjunctive therapy for prostate cancer • Barrigel™ Hyaluronic Acid Rectal Spacer is easily sculpted, highly visible on transrectal ultrasound (TRUS), biodegradable, reversible, and offers one-step assembly in all sites of service • Barrigel™ Spacer is the only hyaluronic acid rectal spacer on the market • It is estimated that there will be 288,000 new cases of prostate cancer diagnosed in the United States in 20231 • Leverages urologist call point established with the UroLift™ System, and opens up access to radiation oncologists CAUTION: Federal (USA) law restricts these devices to sale or use by or on the order of a physician. Refer to the Instructions for Use for a complete listing of the indications, contraindications, warnings, and precautions. Information in this document is not a substitute for the product Instructions for Use. Not all products may be available in all countries. 1. Statistics for Prostate Cancer. 2023. American Cancer Society. KEY TAKEAWAYS

11 Clinical and Commercial Updates Expanding Structural Heart portfolio • In the final stages of completion for the commercial launch for the Wattson™ Temporary Pacing Guidewire (“TPG”) • The Wattson™ TPG is a unique bipolar guidewire used specifically for TAVR and BAV procedures • Wattson™ TPG is engineered to help reduce the risk of ventricular perforation while providing confidence in capture during rapid pacing • As a dual delivery guidewire and pacing wire, Wattson™ TPG will complement our expanding structural heart portfolio, which already includes the MANTA™ Vascular Closure Device for large bore femoral arterial access site closure and the Langston™ Dual-Lumen Catheter for contrast delivery and pressure measurements across the aortic valve CAUTION: Federal (USA) law restricts these devices to sale or use by or on the order of a physician. Refer to the Instructions for Use for a complete listing of the indications, contraindications, warnings, and precautions. Information in this document is not a substitute for the product Instructions for Use. Not all products may be available in all countries. PRODUCT LAUNCH

12 Thomas Powell - Executive VP and CFO Financial Overview

13 Q3'23 Financial Review ◦ GAAP gross margin of 55.8% vs. 54.4% in the prior year period ◦ Adjusted gross margin of 59.4%, up 70 bps year-over-year ◦ GAAP operating margin of 22.1% vs. 19.3% in prior year period ◦ Adjusted operating margin of 27.2%, up 30 bps year-over-year Gross margin Operating margin Global revenue growth ◦ GAAP tax rate of 8.0% vs. 14.5% in prior year period ◦ Adjusted tax rate of 8.0% vs. 9.8% in prior year period Effective tax rate ◦ GAAP EPS of $2.91 vs. $2.16 in prior year period ◦ Adjusted EPS of $3.64, up 11.3% year-over-year Earnings per share ◦ Revenue increased 8.7% year-over-year on a GAAP basis ◦ Revenue increased 7.4% year-over-year on a constant currency basis Note: See appendices for reconciliations of non-GAAP financial information.

14 Acquisition of Palette Life Sciences AB • On a standalone basis, Palette is expected to generate net sales of $56 million in 2023. For 2024, the acquired business is expected to deliver a high-teens to low 20% revenue growth profile. • Acquisition will be immediately accretive to adjusted gross margin and will enhance adjusted operating margin in the near term • Transaction is expected to be dilutive to the Company’s adjusted earnings per share (excluding non-recurring purchase accounting items and other acquisition and integration related costs) in 2023 and 2024 by approximately $0.25 and $0.35, respectively • Beginning in fiscal year 2025, and thereafter, the Company expects the acquisition to be increasingly accretive to adjusted earnings per share (excluding non-recurring purchase accounting items and other acquisition and integration related costs) FINANCIAL GUIDANCE

15 2023 Financial Guidance Summary 2023 Guidance Low High GAAP Revenue Growth 6.25% 6.45% Impact of Foreign Exchange Rate Fluctuations (0.15)% (0.15)% Constant Currency Revenue Growth 6.40% 6.60% Adjusted Gross Margin 59.25% 59.75% Adjusted Operating Margin 26.25% 26.50% Adjusted EPS $13.30 $13.50 Adjusted EPS % Growth 1.8% 3.4% Note: See appendices for reconciliations of non-GAAP information Note: See appendices for reconciliations of non-GAAP financial information.

16 Key Takeaways Our diversified portfolio and global footprint drove durable growth in the third quarter. Our execution remains strong, we are launching new products, and our margins remain healthy. The solid third quarter performance and stable to improving macro environment keeps us well-positioned to deliver on our financial guidance for 2023. We believe that Palette Life Sciences AB will be a meaningful contributor to our growth and enhance adjusted margins in the coming years.

17 17 17 Thank You Teleflex, the Teleflex logo, are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries. © 2023 Teleflex Incorporated. All rights reserved. MCI-2021-0563.

18 Appendices

19 Non-GAAP Financial Measures The presentation to which these appendices are attached and the following appendices include, among other things, tables reconciling the following applicable non-GAAP financial measures to the most comparable GAAP financial measure: ◦ Constant currency revenue growth. This non-GAAP measure is based upon net revenues, adjusted to eliminate the impact of translating the results of international subsidiaries at different currency exchange rates from period to period. The impact of changes in foreign currency may vary significantly from period to period, and such changes generally are outside of the control of our management. We believe that this measure facilitates a comparison of our operating performance exclusive of currency exchange rate fluctuations that do not reflect our underlying performance or business trends. ◦ Adjusted diluted earnings per share. This non-GAAP measure is based upon diluted earnings per share from continuing operations, the most directly comparable GAAP measure, adjusted to exclude, depending on the period presented, the impact of (i) restructuring, restructuring related and impairment items; (ii) acquisition, integration and divestiture related items; (iii) “other items” identified in the reconciliation tables appearing in Appendices A1, A2, A3, and A4, as applicable; (iv) costs incurred in connection with our implementation of a new global ERP solution and related IT transition costs; (v) pension termination and related charges; (vi) certain costs associated with the registration of medical devices under the European Union Medical Device Regulation; (vii) intangible amortization expense; and (viii) tax adjustments. Management does not believe that any of the excluded items are indicative of our underlying core performance or business trends. ◦ Adjusted gross profit and margin. These measures exclude, depending on the period presented, the impacts of (i) restructuring, restructuring related and impairment items, (ii) acquisition, integration and divestiture related items and (iii) “other items” identified in the reconciliation tables appearing in Appendices A1, A2, A3, and A4, as applicable. ◦ Adjusted operating profit and margin. These measures exclude, depending on the period presented, the impact of (i) restructuring, restructuring related and impairment items; (ii) acquisitions, integration and divestiture related items; (iii) “other items” identified in the reconciliation tables appearing in Appendices A1, A2, A3, and A4, as applicable; (iv) costs incurred in connection with our implementation of a new global ERP solution and related IT transition costs; (v) pension termination and related charges; (vi) intangible amortization expense; and (vii) certain costs associated with the registration of medical devices under the European Union Medical Device Regulation. ◦ Adjusted tax rate. This measure is the percentage of the Company’s adjusted taxes on income from continuing operations to its adjusted income from continuing operations before taxes. Adjusted taxes on income from continuing operations excludes, depending on the period presented, the impact of tax benefits or costs associated with (i) restructuring, restructuring related and impairment items; (ii) acquisition, integration and divestiture related items; (iii) “other items” identified in the reconciliation tables appearing in Appendices A1, A2, A3, and A4, as applicable; (iv) costs incurred in connection with our implementation of a new global ERP solution and related IT transition costs; (v) certain costs associated with the registration of medical devices under the European Union Medical Device Regulation; (vi) intangible amortization expense; and (vii) tax adjustments.

20 Non-GAAP Adjustments The following is an explanation of certain of the adjustments that are applied with respect to one or more of the non-GAAP financial measures that appear in the presentation to which these appendices are attached: Restructuring, restructuring related and impairment items - Restructuring programs involve discrete initiatives designed to, among other things, consolidate or relocate manufacturing, administrative and other facilities, outsource distribution operations, improve operating efficiencies and integrate acquired businesses. Depending on the specific restructuring program involved, our restructuring charges may include employee termination, contract termination, facility closure, employee relocation, equipment relocation, outplacement and other exit costs associated with the restructuring program. Restructuring related charges are directly related to our restructuring programs and consist of facility consolidation costs, including accelerated depreciation expense related to facility closures, costs to transfer manufacturing operations between locations, and retention bonuses offered to certain employees as an incentive for them to remain with our company after completion of the restructuring program. Impairment charges occur if, due to events or changes in circumstances, we determine that the carrying value of an asset exceeds its fair value. Impairment charges do not directly affect our liquidity, but could have a material adverse effect on our reported financial results. Acquisition, integration and divestiture related items - Acquisition and integration expenses are incremental charges, other than restructuring or restructuring related expenses, that are directly related to specific business or asset acquisition transactions. These charges may include, among other things, professional, consulting and other fees; systems integration costs; legal entity restructuring expense; inventory step-up amortization (amortization, through cost of goods sold, of the increase in fair value of inventory resulting from a fair value calculation as of the acquisition date); fair value adjustments to contingent consideration liabilities; and bridge loan facility and backstop financing fees in connection with loan facilities that ultimately were not utilized. Divestiture related activities involve specific business or asset sales. Depending primarily on the terms of a divestiture transaction, the carrying value of the divested business or assets on our financial statements and other costs we incur as a direct result of the divestiture transaction, we may recognize a gain or loss in connection with the divestiture related activities. Other items - These are discrete items that occur sporadically and can affect period-to-period comparisons. Pension termination and related charges - These adjustments represent charges associated with the planned termination of the Teleflex Incorporated Retirement Income Plan, a frozen U.S. defined benefit pension plan, and related direct incremental costs. These charges and costs do not represent normal and recurring operating expenses, will be inconsistent in amounts and frequency, and are not expected to recur once the plan termination process has been completed. Accordingly, management has excluded these amounts to facilitate an evaluation of our current operating performance and a comparison to our past operating performance.

21 Non-GAAP Adjustments European medical device regulation - The European Union (“EU”) has adopted the EU Medical Device Regulation (“MDR”), which replaces the existing Medical Devices Directive (“MDD”) and imposes more stringent requirements for the marketing and sale of medical devices in the EU, including requirements affecting clinical evaluations, quality systems and post-market surveillance. The MDR requirements became effective in May 2021, although certain devices that previously satisfied MDD requirements can continue to be marketed in the EU until May 2024, subject to certain limitations. Significantly, the MDR will require the re-registration of previously approved medical devices. As a result, Teleflex will incur expenditures in connection with the new registration of medical devices that previously had been registered under the MDD. Therefore, these expenditures are not considered to be ordinary course expenditures in connection with regulatory matters (in contrast, no adjustment has been made to exclude expenditures related to the registration of medical devices that were not registered previously under the MDD). Intangible amortization expense - Certain intangible assets, including customer relationships, intellectual property, distribution rights, trade names and non-competition agreements, initially are recorded at historical cost and then amortized over their respective estimated useful lives. The amount of such amortization can vary from period to period as a result of, among other things, business or asset acquisitions or dispositions. ERP implementation - These adjustments represent direct and incremental costs incurred in connection with our implementation of a new global enterprise resource planning ("ERP") solution and related IT transition costs. An implementation of this scale is a significant undertaking and will require substantial time and attention of management and key employees. The associated costs do not represent normal and recurring operating expenses and will be inconsistent in amounts and frequency making it difficult to contribute to a meaningful evaluation of our operating performance. Tax adjustments - These adjustments represent the impact of the expiration of applicable statutes of limitations for prior year returns, the resolution of audits, the filing of amended returns with respect to prior tax years and/or tax law or certain other discrete changes affecting our deferred tax liability.

22 Notes: (1) Selling, general and administrative expenses and research and development expenses are shown as a percentage of net revenues. (2) Operating margin defined as Income from continuing operations before interest, loss on extinguishment of debt and taxes as a percentage of net revenues. See slide titled Non-GAAP Adjustments included at the beginning of the appendices to this presentation for Non-GAAP definitions. Totals may not sum due to rounding. Appendix A1 – Reconciliation of Consolidated Statement of Income Items (Dollars in millions, except per share data) Three Months Ended October 1, 2023 Gross margin Selling, general and administrative expenses (1) Research and development expenses (1) Operating margin (2) Income before income taxes Income tax expense Effective income tax rate Diluted earnings per share from continuing operations GAAP Basis 55.8% 28.6% 5.0% 22.1% $149.6 $11.9 8.0% $2.91 Adjustments Restructuring, restructuring related and impairment items (A) 0.5 — — 0.6 4.7 0.7 0.08 Acquisition, integration and divestiture related items (B) — 2.0 — (2.0) (14.8) 0.2 (0.32) ERP Implementation — — — — 0.3 0.1 0.00 MDR — — (0.8) 0.8 5.7 — 0.12 Intangible amortization expense 3.1 (2.6) — 5.7 41.6 2.1 0.85 Tax adjustments — — — — — — — Adjustments total 3.6 (0.6) (0.8) 5.1 37.5 3.1 0.73 Adjusted basis 59.4% 28.0% 4.2% 27.2% $187.1 $15.0 8.0% $3.64

23 Appendix A2 – Reconciliation of Consolidated Statement of Income Items (Dollars in millions, except per share data) Three Months Ended September 25, 2022 Gross margin Selling, general and administrative expenses (1) Research and development expenses (1) Operating margin (2) Income before income taxes Income tax expense Effective income tax rate Diluted earnings per share from continuing operations GAAP Basis 54.4% 30.5% 5.5% 19.3% $119.2 $17.3 14.5% $2.16 Adjustments Restructuring, restructuring related and impairment items (A) 1.0 — — 1.1 7.5 0.5 0.15 Acquisition, integration and divestiture related items (B) — (0.2) — (0.8) (5.2) (1.4) (0.08) ERP Implementation — — — — — — — MDR — — (1.3) 1.3 8.8 — 0.19 Intangible amortization expense 3.3 (2.6) — 6.0 40.9 1.5 0.83 Tax adjustments — — — — — (1.1) 0.02 Adjustments total 4.3 (2.8) (1.3) 7.6 52.0 (0.5) 1.11 Adjusted basis 58.7% 27.7% 4.2% 26.9% $171.2 $16.8 9.8% $3.27 Notes: (1) Selling, general and administrative expenses and research and development expenses are shown as a percentage of net revenues. (2) Operating margin defined as Income from continuing operations before interest, loss on extinguishment of debt and taxes as a percentage of net revenues. See slide titled Non-GAAP Adjustments included at the beginning of the appendices to this presentation for Non-GAAP definitions. Totals may not sum due to rounding.

24 Appendix A3 – Reconciliation of Consolidated Statement of Income Items (Dollars in millions, except per share data) Nine Months Ended October 1, 2023 Gross margin Selling, general and administrative expenses (1) Research and development expenses (1) Operating margin (2) Income before income taxes Income tax expense Effective income tax rate Diluted earnings per share from continuing operations GAAP Basis 55.2% 30.4% 5.4% 19.3% $374.0 $47.7 12.7% $6.90 Adjustments Restructuring, restructuring related and impairment items (A) 0.9 — (0.1) 1.3 27.5 4.2 0.49 Acquisition, integration and divestiture related items (B) — 0.9 — (0.9) (19.3) 0.3 (0.41) ERP Implementation — (0.1) — 0.1 2.8 0.7 0.05 MDR — — (1.1) 1.1 23.6 — 0.50 Intangible amortization expense 3.2 (2.6) — 5.6 125.3 6.2 2.51 Tax adjustments — — — — — (4.8) 0.10 Adjustments total 4.1 (1.8) (1.2) 7.2 159.9 6.6 3.24 Adjusted basis 59.3% 28.6% 4.2% 26.5% $533.9 $54.3 10.2% $10.14 Notes: (1) Selling, general and administrative expenses and research and development expenses are shown as a percentage of net revenues. (2) Operating margin defined as Income from continuing operations before interest, loss on extinguishment of debt and taxes as a percentage of net revenues. See slide titled Non-GAAP Adjustments included at the beginning of the appendices to this presentation for Non-GAAP definitions. Totals may not sum due to rounding.

25 Appendix A4 – Reconciliation of Consolidated Statement of Income Items (Dollars in millions, except per share data) Nine Months Ended September 25, 2022 Gross margin Selling, general and administrative expenses (1) Research and development expenses (1) Operating margin (2) Income before income taxes Income tax expense Effective income tax rate Diluted earnings per share from continuing operations GAAP Basis 54.5% 31.0% 5.5% 18.3% $336.5 $51.7 15.4% $6.02 Adjustments Restructuring, restructuring related and impairment items (A) 1.1 — — 1.2 25.3 2.3 0.49 Acquisition, integration and divestiture related items (B) — (0.1) — (0.2) (4.5) (1.4) (0.07) ERP Implementation — — — — — — — MDR — — (1.5) 1.4 29.4 — 0.62 Intangible amortization expense 3.3 (2.7) — 6.0 122.0 4.6 2.48 Tax adjustments — — — — — — 0.00 Adjustments total 4.4 (2.8) (1.5) 8.4 172.2 5.5 3.52 Adjusted basis 58.9% 28.2% 4.0% 26.7% $508.7 $57.2 11.2% $9.54 Notes: (1) Selling, general and administrative expenses and research and development expenses are shown as a percentage of net revenues. (2) Operating margin defined as Income from continuing operations before interest, loss on extinguishment of debt and taxes as a percentage of net revenues. See slide titled Non-GAAP Adjustments included at the beginning of the appendices to this presentation for Non-GAAP definitions. Totals may not sum due to rounding.

26 Appendix A tickmarks (A) Restructuring, restructuring related and impairment items – For the three months ended October 1, 2023, pre-tax restructuring charges were $0.2 million and restructuring related charges were $4.5 million. For the three months ended September 25, 2022, pre-tax restructuring charges were $0.6 million and restructuring related charges were $6.9 million. For the nine months ended October 1, 2023, pre-tax restructuring charges were $4.0 million and restructuring related charges were $23.6 million. For the nine months ended September 25, 2022, pre-tax restructuring charges were $1.5 million; restructuring related charges were $22.4 million, and impairment charges were $1.5 million. (B) Acquisition, integration and divestiture related items – For the three months ended October 1, 2023, these credits and charges primarily related to a credit recognized due to a decrease in contingent consideration expense resulting from changes in the estimated fair value of our contingent consideration and charges associated with the acquisition of Palette Life Sciences AB. For the three months ended September 25, 2022, these charges related to the acquisition of Standard Bariatrics, Inc. and the gain related to a sale of a building. For the nine months ended October 1, 2023, these credits and charges primarily related to a credit recognized due to a decrease in contingent consideration expense resulting from changes in the estimated fair value of our contingent consideration and charges associated with the acquisition of Palette Life Sciences AB. For the nine months ended September 25, 2022, these charges related to the acquisition of Standard Bariatrics, Inc., the divestiture of respiratory assets, and the gain related to a sale of a building.

27 Appendix B - 2023 Adj. Gross and Operating Margin Guidance Reconciliation Low High Forecasted GAAP Gross Margin 55.30% 55.80% Estimated restructuring, restructuring related and impairment items 0.85% 0.85% Estimated acquisition, integration, and divestiture related items —% —% Estimated intangible amortization expense 3.10% 3.10% Forecasted Adjusted Gross Margin 59.25% 59.75% Low High Forecasted GAAP Operating Margin 16.88% 17.13% Estimated restructuring, restructuring related and impairment items 1.14% 1.14% Estimated acquisition, integration, and divestiture related items (0.32)% (0.32)% Estimated other items 0.01% 0.01% Pension termination and related charges 1.66% 1.66% Estimated ERP implementation 0.10% 0.10% Estimated MDR 0.95% 0.95% Estimated intangible amortization expense 5.83% 5.83% Forecasted Adjusted Operating Margin 26.25% 26.50%

28 Appendix C – Reconciliation of 2023 Adjusted Earnings Per Share Guidance Low High Forecasted GAAP Diluted Earnings Per Share from continuing operations $7.95 $8.15 Estimated restructuring, restructuring related and impairment items, net of tax $0.61 $0.61 Estimated acquisition, integration, and divestiture related items, net of tax -$0.29 -$0.29 Estimated other items, net of tax $0.11 $0.11 Pension termination and related charges, net of tax $0.80 $0.80 Estimated ERP implementation, net of tax $0.05 $0.05 Estimated MDR, net of tax $0.60 $0.60 Estimated intangible amortization expense, net of tax $3.47 $3.47 Forecasted Adjusted Diluted Earnings Per Share from continuing operations, net of tax $13.30 $13.50

29 2023 Segment Revenue Review Nine Months Ended % Increase/ Decrease Dollars in Millions October 1, 2023 September 25, 2022 Reported Revenue Growth Currency Impact Constant Currency Growth Americas $1,264.7 $1,195.7 5.8% —% 5.8% EMEA $433.9 $410.5 5.7% 0.8% 4.9% Asia $258.6 $227.8 13.5% (5.9)% 19.4% OEM $243.4 $199.0 22.4% 0.5% 21.9% Consolidated $2,200.6 $2,033.0 8.2% (0.5)% 8.7%

30 2023 Global Product Category Revenue Review Nine Months Ended % Increase/ Decrease Dollars in Millions October 1, 2023 September 25, 2022 Reported Revenue Growth Currency Impact Constant Currency Growth Vascular Access $521.3 $497.2 4.9% (0.4)% 5.3% Interventional $375.8 $319.9 17.5% (0.6)% 18.1% Anesthesia $291.8 $289.2 0.9% (0.3)% 1.2% Surgical $317.8 $282.5 12.5% (1.6)% 14.1% Interventional Urology $226.8 $233.7 (2.9)% (0.1)% (2.8)% OEM $243.4 $199.0 22.4% 0.5% 21.9% Other $223.7 $211.5 5.7% 0.2% 5.5% Consolidated $2,200.6 $2,033.0 8.2% (0.5)% 8.7% ◦ 1. Includes revenues generated from sales of the Company’s respiratory and urology products (other than interventional urology products).

31 2023 Financial Review - Nine Months Ended October 1, 2023 ◦ GAAP gross margin of 55.2% vs. 54.5% in the prior year period ◦ Adjusted gross margin of 59.3%, up 40 bps year-over-year ◦ GAAP operating margin of 19.3% vs. 18.3% in prior year period ◦ Adjusted operating margin of 26.5%, down 20 bps year-over-year Gross margin Operating margin Global revenue growth ◦ GAAP tax rate of 12.7% vs. 15.4% in prior year period ◦ Adjusted tax rate of 10.2% vs. 11.2% in prior year period Effective tax rate ◦ GAAP EPS of $6.90 vs. $6.02 in prior year period ◦ Adjusted EPS of $10.14, up 6.3% year-over-year Earnings per share ◦ Revenue increased 8.2% year-over-year on a GAAP basis ◦ Revenue increased 8.7% year-over-year on a constant currency basis Note: See appendices for reconciliations of non-GAAP financial information.

8-K Cover Page	Nov. 02, 2023
Cover [Abstract]
Document Type	8-K
Entity Registrant Name	TELEFLEX INCORPORATED
Document Period End Date	Nov. 02, 2023
Entity Incorporation, State or Country Code	DE
Entity File Number	1-5353
Entity Tax Identification Number	23-1147939
Entity Address, Address Line One	550 E. Swedesford Rd., Suite 400
Entity Address, City or Town	Wayne,
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	19087
City Area Code	(610)
Local Phone Number	225-6800
Title of 12(b) Security	Common Stock, par value $1 per share
Trading Symbol	TFX
Security Exchange Name	NYSE
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Entity Emerging Growth Company	false
Entity Central Index Key	0000096943
Amendment Flag	false